PRLD vs. SKYE, IXHL, CRVO, PRQR, IMAB, INCR, RGLS, GOSS, MCRB, and ACET
Should you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Skye Bioscience (SKYE), Incannex Healthcare (IXHL), CervoMed (CRVO), ProQR Therapeutics (PRQR), I-Mab (IMAB), InterCure (INCR), Regulus Therapeutics (RGLS), Gossamer Bio (GOSS), Seres Therapeutics (MCRB), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
In the previous week, Skye Bioscience had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Skye Bioscience and 2 mentions for Prelude Therapeutics. Skye Bioscience's average media sentiment score of 0.29 beat Prelude Therapeutics' score of -0.43 indicating that Prelude Therapeutics is being referred to more favorably in the news media.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by company insiders. Comparatively, 79.5% of Prelude Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500.
Skye Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 86.72%. Prelude Therapeutics has a consensus price target of $5.25, indicating a potential upside of 31.25%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Skye Bioscience is more favorable than Prelude Therapeutics.
Prelude Therapeutics received 24 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
Skye Bioscience's return on equity of -52.97% beat Prelude Therapeutics' return on equity.
Summary
Skye Bioscience beats Prelude Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Prelude Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prelude Therapeutics Competitors List
Related Companies and Tools
